MICROBA LIFE SCIENCES LIMITED

*Disclaimer

MICROBA LIFE SCIENCES LIMITED (ASX: MAP)

🔗 📄 📈

MAP: First Distribution Agreement Executed with Sonic Healthcare

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences Limited has signed a commercial contract with Sonic Healthcare Limited, through its subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba's MetaPanel™ infectious disease test in Australia.
This agreement is the first between Microba and Sonic Healthcare since Sonic's strategic investment of $17.8 million into Microba on 29 November 2022.
Sonic Healthcare now has exclusive distribution rights to provide the MetaPanel™ test across Australia through its Pathology network, marking the completion of the first of their commercial distribution agreements.

2023-07-05 09:07:00

MAP: Microba Commences Phase I Clinical Trial for IBD Therapeutic

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences Limited announces the successful dosing of the first participants in the Phase I Clinical Trial of its potential new treatment for ulcerative colitis, a drug candidate known as MAP 315.
The trial, which is a randomised, double-blind, placebo-controlled study on 32 healthy adults, is being conducted by Nucleus Network in Melbourne, Australia and is aligned with FDA pre-IND engagement.
Results from the trial, featuring two cohorts of 16 participants each receiving MAP 315 or a matching placebo for 14 consecutive days, are expected to be available by December 2023.

2023-06-28 09:04:00

MAP: MRFF Grant Awarded to QUT, In Collaboration With Microba

MICROBA LIFE SCIENCES LIMITED

The Medical Research Future Fund (MRFF) has awarded a $2.92m grant to Queensland University of Technology (QUT) and Microba to establish the world's most comprehensive human microbiome biobank.
This collaboration will lead to the isolation and characterization of thousands of new bacterial species from the human microbiome.
The Australian Human Microbiome Biobank (AHMB) will be a globally unique asset with the potential to enable numerous therapeutic programs and partnerships.

2023-06-27 11:17:00

MAP: Microba receives two AusIndustry Advanced Overseas Findings

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences has received approval for two additional Advanced Overseas Findings for its IBD and Immuno-oncology programs.
The findings cover an estimated $1,210,000 in overseas expenditure, potentially resulting in $526,000 in R&D Tax Incentive cash rebates.
Eligible overseas and Australian R&D expenditures for these programs will receive a 43.5% cash rebate under the Australian Government's R&D Tax Incentive Program.

2023-06-14 14:06:00

MAP: SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia

MICROBA LIFE SCIENCES LIMITED

Microba has executed four further distribution agreements with SYNLAB affiliate organizations in Poland, Hungary, Romania & Croatia.
This expansion follows the new agreements executed with SYNLAB affiliate organizations in March 2023 for Türkiye and Czech Republic.
Further affiliate country agreements are anticipated to be completed in the near term to continue the expansion activity with SYNLAB.

2023-04-13 09:10:00

MAP: Microba Receives Ethics Approval for Phase 1 Clinical Trial

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences has received HREC approval for its Phase 1 clinical trial of novel drug candidate MAP 315 for ulcerative colitis treatment.
Phase 1 trial will involve 32 healthy participants and evaluate safety, tolerability, and pharmacokinetics of MAP 315 in a randomized, double-blind, placebo-controlled study.
MAP 315 has the potential to fill a significant gap in the existing treatment options for ulcerative colitis, a debilitating condition affecting over 7 million people worldwide.

2023-03-29 14:39:00

MAP: SYNLAB Agreements Signed in Turkiye and Czech Republic

MICROBA LIFE SCIENCES LIMITED

Microba has signed agreements with SYNLAB International GmbH affiliates Referans M-B Saglik Labopratuvar and SYNLAB Czech s.r.o. to distribute its testing technology into Türkiye and Czech Republic respectively.
The agreements provide SYNLAB affiliate organisations with non-exclusive distribution rights out to 31 December 2028.
Additional affiliate country agreements are expected to be completed in the near future.

2023-03-02 09:07:00

MAP: Microba Launches Next Generation Healthcare Testing

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences Limited has launched their next-generation human gut microbiome testing product range, MetaXplore™ in Australia.
The range consists of 3 products with features such as easy to interpret report formats, scientifically graded clinical insights and diagnostic pathogen and parasite detection.
The range is expected to expand the total addressable market for Microba’s testing products.

2023-02-28 09:01:00

MAP: US Distribution Agreement Signed with Luminary Health

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences Limited has signed a distribution agreement with Luminary Health Centers Inc. to distribute a microbiome test powered by Microba’s testing technology to consumers in the United States.
The agreement provides non-exclusive distribution rights out to 2027 and the initial 12 month phase has a value of USD $458,000 to Microba.
This partnership expands Microba's distribution base to deliver its testing technology to clinicians, patients and consumers.

2023-02-07 09:01:00

MAP: Positive first animal data for Cancer Program

MICROBA LIFE SCIENCES LIMITED

Microba Life Sciences Limited has announced the completion of its Immuno-oncology Program’s first animal studies, producing positive results.
The study showed a significant reduction in melanoma tumour volume for mice treated with an immune checkpoint inhibitor and Microba's therapeutic leads.
These results provide a roadmap to clinical translation, demonstrating the impact the microbiome can have in improving response to ICI therapy.

2023-02-01 09:28:00

ASX Briefs...everything...in 3 bullet points

ASX Briefs

*Disclaimer

MICROBA LIFE SCIENCES LIMITED (ASX: MAP)

MAP: First Distribution Agreement Executed with Sonic Healthcare

MICROBA LIFE SCIENCES LIMITED

MAP: Microba Commences Phase I Clinical Trial for IBD Therapeutic

MICROBA LIFE SCIENCES LIMITED

MAP: MRFF Grant Awarded to QUT, In Collaboration With Microba

MICROBA LIFE SCIENCES LIMITED

MAP: Microba receives two AusIndustry Advanced Overseas Findings

MICROBA LIFE SCIENCES LIMITED

MAP: SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia

MICROBA LIFE SCIENCES LIMITED

MAP: Microba Receives Ethics Approval for Phase 1 Clinical Trial

MICROBA LIFE SCIENCES LIMITED

MAP: SYNLAB Agreements Signed in Turkiye and Czech Republic

MICROBA LIFE SCIENCES LIMITED

MAP: Microba Launches Next Generation Healthcare Testing

MICROBA LIFE SCIENCES LIMITED

MAP: US Distribution Agreement Signed with Luminary Health

MICROBA LIFE SCIENCES LIMITED

MAP: Positive first animal data for Cancer Program

MICROBA LIFE SCIENCES LIMITED